Bcl-2 protein level in blood of patients with acute myeloid leukaemia
Bruno Baudin(Université Paris Cité), Michel Vaubourdolle(Sorbonne Université), Agnès Mailloux(Sorbonne Université), Laurent Garderet(Inserm), Patricia Zunic(Sorbonne Université), Françoise Isnard(Sorbonne Université), Abdelkrim Tahraoui(Badji Mokhtar-Annaba University), Bénédicte Bénéteau‐Burnat(Sorbonne Université)
Unknown
January 1, 2008
Cited by 0
Related Papers
Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice
|Bone Marrow Transplantation|2013|310
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2023|134
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
|Nature Medicine|2024|109
Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
|American Journal of Hematology|2013|101